Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05951192 · ClinicalTrials.gov registry record · Phase 4

A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease

A Phase 4 study of Anemia and Renal Insufficiency, Chronic, sponsored by USRC Kidney Research.

Completed
Registry status
Phase 4
Development phase
161
Enrollment target
1
Study location

NCT05951192 is a Phase 4 study of Anemia and Renal Insufficiency, Chronic that has completed, run by USRC Kidney Research. The registered enrollment target is 161 participants, below the 425-participant average among 72 other Anemia trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05951192, a Phase 4 study of Anemia and Renal Insufficiency, Chronic, has completed, sponsored by USRC Kidney Research.

COMPLETED
Registry status
Phase 4
Development phase
161 participants
Enrollment target
1
Study location

Study Summary

Investigator-initiated, interventional, prospective study to assess the clinical and operational effectiveness of daprodustat in adult patients receiving in center hemodialysis or peritoneal home dialysis who are transitioning from Mircera to daprodustat.

Interventions

  • DRUG Daprodustat

Study Locations (1)

Colorado

  • USRC Kidney Research - Lone Tree

Trial Details

FieldValue
Enrollment Target 161 participants
Start Date 2023-07-01
Est. Completion 2024-02-14
Phase Phase 4

Sponsor

USRC Kidney Research

4 total trials

What the Registry Record Tells You About NCT05951192

The ClinicalTrials.gov registry entry for NCT05951192 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 425-participant average among 72 other Anemia trials with a reported enrollment target (62% lower). The listed sponsor is USRC Kidney Research, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Anemia appearing as the primary indexed condition, and to 1 intervention - of which Daprodustat is the first listed.

NCT05951192 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT05951192 about?

NCT05951192 is a clinical study titled "A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease". Investigator-initiated, interventional, prospective study to assess the clinical and operational effectiveness of daprodustat in adult patients receiving in center hemodialysis or peritoneal home dialysis who are transitioning from Mircera to daprodustat.

What is the current status of trial NCT05951192?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 161 participants. The study started on 2023-07-01. Estimated completion is 2024-02-14.

What conditions does trial NCT05951192 study?

This clinical trial studies the following conditions: Anemia, Renal Insufficiency, Chronic, Renal Anemia.

What interventions are being tested in trial NCT05951192?

The interventions under investigation include: Daprodustat (DRUG).

Who is sponsoring clinical trial NCT05951192?

This trial is sponsored by USRC Kidney Research, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05951192 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.